期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 20, 期 9, 页码 632-+出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2020.04.020
关键词
Anakinra; CAR-T cell therapy; Cytokine release syndrome; Multiple myeloma; Tocilizumab
资金
- Tisch Cancer Institute at Mount Sinai [1R01CA244899-01A1]
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CAR-T) cell therapy has demonstrated promising clinical efficacy in myeloma but is accompanied by cytokine release syndrome (CRS), wherein clinical management is challenging owing to lack of therapeutic options. Interleukin (IL)-6 inhibition with the monoclonal antibody tocilizumab, administered alone or with steroids is the most common approach for treating CRS currently. Anti-IL-1 therapy has a strong preclinical scientific rationale for CRS mitigation after CAR-T cell therapy and may complement current approaches. We contrast clinical features and laboratory parameters from 2 patients having CRS post anti-BCMA CAR-T infusion for myeloma, 1 treated with tocilizumab alone and the other illustrating the use of adjunctive anti-IL-1R therapy with anakinra. We therefore see merit in the use of IL-1 inhibition as a valuable adjunct in the management of CRS following CAR-T therapy in myeloma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据